Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Earlier, PolyPid Raises $26.7M Via Immediate Warrant Exercises To Extend Runway Beyond Anticipated FDA Approval Of D-PLEX

Author: Benzinga Newsdesk | June 17, 2025 01:39am
  • The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration ("FDA") Approval of D-PLEX₁₀₀.
  • The Company Recently Announced Successful Topline Results from its Phase 3 SHIELD II Trial; D-PLEX₁₀₀ Demonstrated a Statistically Significant Reduction in Surgical Site Infections ("SSIs") and Successfully Met the Study's Primary Endpoint and all Key Secondary Endpoints.

Posted In: PYPD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist